At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
MicroMatrix® and Cytal™ Wound Matrix 2-Layer +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Site Randomized, Clinical Trial Comparing the Concomitant Use of MicroMatrix® With Cytal™ Wound Matrix 2-Layer to Standard of Care in Patients With Stage 3 or 4 Pressure Injuries
In Brief
A clinical study evaluating MicroMatrix® and Cytal™ Wound Matrix 2-Layer, MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT, and 1 other intervention for Pressure Ulcers Stage III and 2 related conditions. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 \& 4 pressure ulcers using ACell products.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsSt Vincent's Hospital
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartApr 2017
First PostedSep 2017
Primary CompletionSep 2019
Study CompletionDec 2019
TodayJul 2026
First PostedSep 14, 2017
Enrollment StartApr 1, 2017
Primary CompletionSep 25, 2019
Study CompletionDec 23, 2019
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.8 years ago
Interventions
MicroMatrix® and Cytal™ Wound Matrix 2-Layerdevice
MicroMatrix® and Cytal™ Wound Matrix 2-Layer
MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWTdevice
MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
Negative Pressure Wound Therapydevice
Negative Pressure Wound Therapy